Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection

Vaccine

Volumn 32, Issue 49, 2014, Pages 6659-6666

  Ghasemi, Amir ^a   Jeddi Tehrani, Mahmood ^b   Mautner, Josef ^c   Salari, Mohammad Hossein ^d   Zarnani, Amir Hassan ^b,e  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Brucella; Molecular chaperon; Recombinant protein; Vaccine

Indexed keywords

BRUCELLA VACCINE; CYTOPLASM PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN 31; PROTEIN DNAK; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TRIGGER FACTOR PROTEIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CHAPERONE; CYTOKINE; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN G; OMP31 PROTEIN, BRUCELLA MELITENSIS; RECOMBINANT VACCINE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TH1 CELL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE; SECRETION (PROCESS);

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BRUCELLA MELITENSIS; BRUCELLA VACCINE; BRUCELLOSIS; CELL PROLIFERATION; CLONING, MOLECULAR; CYTOKINES; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HEAT-SHOCK PROTEINS; IMMUNOGLOBULIN G; LYMPHOCYTES; MICE, INBRED BALB C; MOLECULAR CHAPERONES; RECOMBINANT PROTEINS; VACCINES, COMBINED; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84922647217     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.013     Document Type: Article

References (57)

1. Van der Henst C., de Barsy M., Zorreguieta A., Letesson J.J., De Bolle X. The Brucella pathogens are polarized bacteria. Microbes Infect 2013, 15:998-1004.
2. Pappas G., Akritidis N., Bosilkovski M., Tsianos E., Brucellosis N Engl J Med 2005, 352:2325-2336.
3. Olsen S.C. Recent developments in livestock and wildlife brucellosis vaccination. Rev Sci Tech 2013, 32:207-217.
4. Avila-Calderon E.D., Lopez-Merino A., Sriranganathan N., Boyle S.M., Contreras-Rodriguez A. A history of the development of Brucella vaccines. Bio-Med Res Int 2013, 2013:743509.
5. Garin-Bastuji B., Blasco J.M., Grayon M., Verger J.M. Brucella melitensis infection in sheep: present and future. Vet Res 1998, 29:255-274.
6. Refai M. Incidence and control of brucellosis in the near east region. Vet Microbiol 2002, 90:81-110.
7. Gupta V.K., Radhakrishnan G., Harms J., Splitter G. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis. Vaccine 2012, 30:4017-4022.
8. Ghasemi A., Zarnani A.H., Ghoodjani A., Rezania S., Salari M.H., Jeddi-Tehrani M. Identification of a new immunogenic candidate conferring protection against Brucella melitensis infection in mice. Mol Immunol 2014, 62:142-149.
9. Jain S., Afley P., Dohre S.K., Saxena N., Kumar S. Evaluation of immunogenicity and protective efficacy of a plasmid DNA vaccine encoding ribosomal protein L9 of Brucella abortus in BALB/c mice. Vaccine 2014, 32:4537-4542.
10. Clausse M., Diaz A.G., Ghersi G., Zylberman V., Cassataro J., Giambartolomei G.H., et al. The vaccine candidate BLSOmp31 protects mice against Brucella canis infection. Vaccine 2013, 31:6129-6135.
11. Riquelme-Neira R., Retamal-Diaz A., Acuna F., Riquelme P., Rivera A., Saez D., et al. Protective effect of a DNA vaccine containing an open reading frame with homology to an ABC-type transporter present in the genomic island 3 of Brucella abortus in BALB/c mice. Vaccine 2013, 31:3663-3667.
12. Li X., Xu J., Xie Y., Qiu Y., Fu S., Yuan X., et al. Vaccination with recombinant flagellar proteins FlgJ and FliN induce protection against Brucella abortus 544 infection in BALB/c mice. Vet Microbiol 2012, 161:137-144.
13. Fu S., Xu J., Li X., Xie Y., Qiu Y., Du X., et al. Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection. PLoS One 2012, 7:e29552.
14. Kaushik P., Singh D.K., Kumar S.V., Tiwari A.K., Shukla G., Dayal S., et al. Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides. Vet Res Commun 2010, 34:119-132.
15. Al-Mariri A., Mahmoud N.H., Hammoud R. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice. Biologicals 2012, 40:140-145.
16. Yang Y., Yin J., Guo D., Lang X., Wang X. Immunization of mice with recombinant S-adenosyl-l-homocysteine hydrolase protein confers protection against Brucella melitensis infection. FEMS Immunol Med Microbiol 2011, 61:159-167.
17. Yang Y., Wang L., Yin J., Wang X., Cheng S., Lang X., et al. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol 2011, 49:175-184.
18. Pasquevich K.A., Estein S.M., Garcia Samartino C., Zwerdling A., Coria L.M., Barrionuevo P., et al. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection. Infect Immun 2009, 77:436-445.
19. Hamer I., Goffin E., De Bolle X., Letesson J.J., Jadot M. Replication of Brucella abortus and Brucella melitensis in fibroblasts does not require Atg5-dependent macroautophagy. BMC Microbiol 2014, 14:223.
20. Ghasemi A., Salari M.H., Zarnani A.H., Pourmand M.R., Ahmadi H., Mirshafiey A., et al. Immune reactivity of Brucella melitensis-vaccinated rabbit serum with recombinant Omp31 and DnaK proteins. Iran J Microbiol 2013, 5:19-23.
21. Bardwell J.C., Craig E.A. Major heat shock gene of Drosophila and the Escherichia coli heat-inducible dnaK gene are homologous. Proc Natl Acad Sci USA 1984, 81:848-852.
22. Zhu X., Zhao X., Burkholder W.F., Gragerov A., Ogata C.M., Gottesman M.E., et al. Structural analysis of substrate binding by the molecular chaperone DnaK. Science 1996, 272:1606-1614.
23. Delpino M.V., Estein S.M., Fossati C.A., Baldi P.C., Cassataro J. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice. Vaccine 2007, 25:6721-6729.
24. Kohler S., Teyssier J., Cloeckaert A., Rouot B., Liautard J.P. Participation of the molecular chaperone DnaK in intracellular growth of Brucella suis within U937-derived phagocytes. Mol Microbiol 1996, 20:701-712.
25. Estein S.M., Cassataro J., Vizcaino N., Zygmunt M.S., Cloeckaert A., Bowden R.A. The recombinant Omp31 from Brucella melitensis alone or associated with rough lipopolysaccharide induces protection against Brucella ovis infection in BALB/c mice. Microbes Infect 2003, 5:85-93.
26. Cassataro J., Estein S.M., Pasquevich K.A., Velikovsky C.A., de la Barrera S., Bowden R., et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun 2005, 73:8079-8088.
27. Yang X., Hudson M., Walters N., Bargatze R.F., Pascual D.W. Selection of protective epitopes for Brucella melitensis by DNA vaccination. Infect Immun 2005, 73:7297-7303.
28. Ghasemi A., Salari M.H., Zarnani A.H., Pourmand M.R., Ahmadi H., Shirazi M.H., et al. Immunogenicity assessment of Brucella mellitensis HSP and TF proteins by immunized rabbit serum. Iran J Allergy Asthma Immunol 2013, 12:192-194.
29. Ghasemi A., Ranjbar R., Amani J. In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate. Iran J Basic Med Sci 2014, 17:172-180.
30. Yang X., Walters N., Robison A., Trunkle T., Pascual D.W. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 2007, 25:2261-2268.
31. Contreras-Rodriguez A., Ramirez-Zavala B., Contreras A., Schurig G.G., Sriranganathan N., Lopez-Merino A. Purification and characterization of an immunogenic aminopeptidase of Brucella melitensis. Infect Immun 2003, 71:5238-5244.
32. Ghasemi A., Salari M.H., Pourmand M.R., Zarnani A.H., Ahmadi H., Shirazi M.H., et al. Optimization and efficient purification in production of Brucella melitensis recombinant HSP A and TF proteins with low endotoxin contents. Jundishapur J Microbiol 2013, 6:e6875.
33. Aida Y., Pabst M.J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990, 132:191-195.
34. Liu C.L., Nikas Y.J., Blankschtein D. Novel bioseparations using two-phase aqueous micellar systems. Biotechnol Bioeng 1996, 52:185-192.
35. Reichelt P., Schwarz C., Donzeau M. Single step protocol to purify recombinant proteins with low endotoxin contents. Protein Expr Purif 2006, 46:483-488.
36. Stoscheck C.M. Quantitation of protein. Methods Enzymol 1990, 182:50-68.
37. Gonzalez D., Grillo M.J., De Miguel M.J., Ali T., Arce-Gorvel V., Delrue R.M., et al. Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One 2008, 3:e2760.
38. Al-Mariri A., Tibor A., Mertens P., De Bolle X., Michel P., Godefroid J., et al. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 2001, 69:4816-4822.
39. Cassataro J., Velikovsky C.A., de la Barrera S., Estein S.M., Bruno L., Bowden R., et al. A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response. Infect Immun 2005, 73:6537-6546.
40. Luo D., Ni B., Li P., Shi W., Zhang S., Han Y., et al. Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of Brucella abortus in BALB/c mice. Infect Immun 2006, 74:2734-2741.
41. Tabynov K., Kydyrbayev Z., Ryskeldinova S., Yespembetov B., Zinina N., Assanzhanova N., et al. Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection. Vaccine 2014, 32:2034-2041.
42. Cheers C. Pathogenesis and cellular immunity in experimental murine brucellosis. Dev Biol Stand 1984, 56:237-246.
43. Murphy E.A., Sathiyaseelan J., Parent M.A., Zou B., Baldwin C.L. Interferon-gamma is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c mice. Immunology 2001, 103:511-518.
44. Zhan Y., Cheers C. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 1993, 61:4899-4901.
45. Baldwin C.L., Parent M. Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection. Vet Microbiol 2002, 90:367-382.
46. Paranavitana C., Zelazowska E., Izadjoo M., Hoover D. Interferon-gamma associated cytokines and chemokines produced by spleen cells from Brucella-immune mice. Cytokine 2005, 30:86-92.
47. Ko J., Splitter G.A. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev 2003, 16:65-78.
48. Gusev N.B., Bogatcheva N.V., Marston S.B. Structure and properties of small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins. Biochemistry (Moscow) 2002, 67:511-519.
49. Munchbach M., Nocker A., Narberhaus F. Multiple small heat shock proteins in rhizobia. J Bacteriol 1999, 181:83-90.
50. Haslbeck M., Buchner J. Chaperone function of sHsps. Prog Mol Subcell Biol 2002, 28:37-59.
51. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008, 14:109-119.
52. Dalrymple S.A., Lucian L.A., Slattery R., McNeil T., Aud D.M., Fuchino S., et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun 1995, 63:2262-2268.
53. Clapp B., Skyberg J.A., Yang X., Thornburg T., Walters N., Pascual D.W. Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses. Infect Immun 2011, 79:4165-4174.
54. Al-Mariri A. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein. Vaccine 2010, 28:1766-1770.
55. Commander N.J., Spencer S.A., Wren B.W., MacMillan A.P. The identification of two protective DNA vaccines from a panel of five plasmid constructs encoding Brucella melitensis 16M genes. Vaccine 2007, 25:43-54.
56. Cassataro J., Pasquevich K.A., Estein S.M., Laplagne D.A., Velikovsky C.A., de la Barrera S., et al. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination. Vaccine 2007, 25:4437-4446.
57. Igietseme J.U., Eko F.O., Black C.M. Contemporary approaches to designing and evaluating vaccines against chlamydia. Expert Rev Vaccines 2003, 2:129-146.